Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Calidi Biotherapeutics, Inc.

  • SAN DIEGO, California
  • Public · NYSE: CLDI
  • 29 employees
$3.3MMarket cap
$45.0KRevenue · FY2022
-$19.9MNet income
29Employees
CLDINYSE
2023IPO

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2022
$45.0K
Net income
-$19.9M
Total assets
$8.9M
Market cap
$3.3M

Source: SEC EDGAR · updated Jun 8, 2026

NYSE: CLDI

15-minute delayed · data by Polygon.io

Market cap
$3.3M
Open
Day range
Prev close
Volume
IPO date
Sep 13, 2023

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Calidi Biotherapeutics, Inc..

Write a review
Explore

Similar companies

Browse all →